Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RCM-106
- Development stage
- Unknown
- Lead developer
- RMIT University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RCM-106 (RMIT Chinese Medicine-106) is a newly formulated Chinese herbal medicine developed for the management of atopic dermatitis (AD), particularly in children. It is being evaluated in a randomized, double-blind, placebo-controlled clinical trial to assess its efficacy and safety for moderate-to-severe AD. The formula was designed based on systematic reviews of traditional Chinese medicine (TCM) treatments for AD and refined with input from dermatology experts. The mechanism of action is not specified but as a TCM herbal formula, it likely acts through multiple pathways relevant to inflammation and skin health[1][2].
Beyond the preview
Go deeper on RCM-106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RCM-106.